Meeting
2022 ASCO Annual Meeting
Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.
Authors
James J. Harding
Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY
James J. Harding , Sarina Anne Piha-Paul , Ronak H. Shah , James M. Cleary , David I. Quinn , Irene Brana , Victor Moreno , Mitesh J. Borad , Sherene Loi , Iben Spanggaard , James M. Ford , Daniel DiPrimeo , Michael F. Berger , Lisa DeFazio Eli , Funda Meric-Bernstam , David B. Solit , Ghassan K. Abou-Alfa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01953926
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4079)
DOI
10.1200/JCO.2022.40.16_suppl.4079
Abstract #
4079
Poster Bd #
67
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT ‘basket’ trial.
First Author: James J. Harding
Poster
2021 ASCO Annual Meeting
Clinical outcomes analysis of TP53-mutated advanced and metastatic biliary tract cancers.
First Author: Sunyoung S. Lee
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Characterizing outcomes of ERBB2-amplified biliary tract cancer.
First Author: Daniel Aaron Fox
Poster
2023 ASCO Annual Meeting
A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.
First Author: Li Jingjing